11/12/2025
ليش ما نفضل أبر التنحيف (الأوزيمبك، الويجوفي، والمونجارو) كعلاج للسمنة بعيادتنا؟
للإطلاع على مصادر ونتائج الدراسات المذكورة:
PMID: 39719170 — Conclusions: “Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass.”
PMID: 39424950 — Abstract: “Notably, patients on GLP-1 RAs exhibited a 195% higher risk of major depression, a 108% increased risk for anxiety, and a 106% elevated risk for suicidal behavior.”
PMID: 33273810 — Conclusion: Over half of T2DM patients initiating GLP-1 RA were non-adherent and the majority (70.1%) discontinued therapy by 24 months. Reasons for non-adherence and discontinuation merit further research.
DOI: 10.1101/2025.06.09.25328726 — Findings: “Weight regain was estimated to plateau at 75.6% (95% CI 68.5-82.7) of the weight lost on treatment.”
ECO 2025 abstract: Weight regain following the cessation of GLP-1 RAs for weight management: a systematic review and meta-analysis — Conclusions: “Cessation of GLP-1 RAs leads to return to baseline weight in less than 2 years with no difference to control groups in less than 1 year.”
— من عيادة التغذية العلاجية للدكتور براء عباس الزبيدي
للحجز والاستفسار التواصل عبر بريد الصفحة
العنوان: بغداد - حي الجامعة - شارع ٦٦ - مجمع تاج الماس الطبي
#صحة #دايت #وزن #تنحيف #صيام #تغذية
